Persistence of antimuscarinic drug use

European Journal of Clinical Pharmacology

Volumn 65, Issue 3, 2009, Pages 309-314

  Brostrøm, Søren ^a   Hallas, Jesper ^b  

^a GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Adherence; Antimuscarinic drugs; Overactive bladder syndrome; Persistence; Pharmacoepidemiology; Pharmacological therapy

Indexed keywords

DARIFENACIN; EMEPRONIUM BROMIDE; EMEPRONIUM CARRAGEENATE; FLAVOXATE; MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; SOLIFENACIN; SPASMOPLEX; TOLTERODINE; TROSPIUM CHLORIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; DRUG EFFECT; DRUG EFFICACY; DRUG USE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERACTIVE BLADDER; PRESCRIPTION; PRIORITY JOURNAL;

AGED; DATABASES, FACTUAL; DENMARK; DRUG ADMINISTRATION SCHEDULE; DRUG PRESCRIPTIONS; DRUG UTILIZATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MUSCARINIC ANTAGONISTS; NORTROPANES; PATIENT COMPLIANCE; QUALITY OF LIFE; URINARY BLADDER, OVERACTIVE;

EID: 60549099163     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-008-0600-9     Document Type: Article

References (24)

1. P Abrams L Cardozo M Fall D Griffiths P Rosier U Ulmsten P van Kerrebroeck A Victor A Wein 2002 The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society Neurourol.Urodyn 21 167 178
2. I Milsom P Abrams L Cardozo RG Roberts J Thuroff AJ Wein 2001 How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study BJU Int 87 760 766
3. SM Finney KE Andersson JI Gillespie LH Stewart 2006 Antimuscarinic drugs in detrusor overactivity and the overactive bladder syndrome: motor or sensory actions BJU Int 98 503 507
4. P Abrams KE Andersson JJ Buccafusco C Chapple WC de Groat AD Fryer G Kay A Laties NM Nathanson PJ Pasricha AJ Wein 2006 Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder Br J Pharmacol 148 565 578
5. G Nabi JD Cody G Ellis P Herbison J Hay-Smith 2006 Anticholinergic drugs versus placebo for overactive bladder syndrome in adults Cochrane Database Syst Rev 4 CD003781
6. M Halaska G Ralph A Wiedemann G Primus B Ballering-Bruhl K Hofner U Jonas 2003 Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability World J Urol 20 392 399
7. F Haab L Cardozo C Chapple AM Ridder 2005 Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome Eur Urol 47 376 384
8. K Kreder C Mayne U Jonas 2002 Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder Eur Urol 41 588 595
9. F Haab J Corcos P Siami K Glavind P Dwyer M Steel F Kawakami K Lheritier WD Steers 2006 Long-term treatment with darifenacin for overactive bladder: results of a 2-year, open-label extension study BJU Int 98 1025 1032
10. YF Yu MB Nichol AP Yu J Ahn 2005 Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the California Medicaid program Value Health 8 495 505
11. FT Shaya S Blume A Gu T Zyczynski Z Jumadilova 2005 Persistence with overactive bladder pharmacotherapy in a Medicaid population Am J Managed Care 11 S121 S129
12. MA Chui 2004 Patient persistence with medication for overactive bladder Value Health 7 366
13. Z Zhou C Barr Y Torigoe T Williamson 2001 Persistence of therapy with drugs for overactive bladder Value Health 4 161
14. CJ Kelleher LD Cardozo V Khullar S Salvatore 1997 A medium-term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance Br J Obstet Gynaecol 104 988 993
15. EK Saks G Northington M Gopal L Arya 2006 Adherence to anti-cholinergic medications in women with urge incontinence Int Urogyn J 7 5398
16. D Gaist HT Sørensen J Hallas 1997 The Danish prescription registers Dan Med Bull 44 445 448
17. J Hallas H Stovring 2006 Templates for analysis of individual-level prescription data Basic Clin Pharmacol Toxicol 98 260 265
18. J Hallas D Gaist L Bjerrum 1997 The waiting-time distribution for prescription drugs Epidemiology 8 666 670
19. DR Cox 1972 Regression models and life tables J R Stat Soc B 34 187 220
20. C Bourgault M Sénécal M Brisson MA Marentette J-P Grégoire 2005 Persistence and discontinuation patterns of antihypertensive therapy among newly treated patients: a population-based study J Human Hypertens 19 607 613
21. Pesce F, Rubilotta E, D'Amico A, Siracusano S, Righetti R, Celia A, Tiberio A, Artibani W (2003) Long-term anticholinergic therapy: duration and causes of discontinuation. Abstract 304 [poster]. International Continence Society 2003, 25-27 August 2003, Paris, France
22. L Brubaker M Nichol K Fanning R Becker Z Jumadilova J Benner 2006 Patient-reported reasons for discontinuing overactive bladder (OAB) medications Neurourol Urodyn 25 614
23. CR Chapple R Martinez-Garcia L Selvaggi P Toozs-Hobson W Warnack T Drogendijk DM Wright J Bolodeoku 2005 A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial Eur Urol 48 464 470
24. SJ Boccuzzi TK Le J Wogen T Williamson 2002 Utilization patterns associated with tolterodine immediate release versus oxybutinin in the management of urinary incontinence (UI) Value Health 5 274